Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
Tomás Pascual,1 Mafalda Oliveira,1,2,3 Patricia Villagrasa,1 Vanesa Ortega,2,3 Laia Paré,1 Begoña Bermejo,4 Serafín Morales,5 Kepa Amillano,6 Rafael López,7 Patricia Galván,8 Jordi Canes,1 Fernando Salvador,1 Paolo Nuciforo,9 Isabel T. Rubio,3 Antonio Llombart-Cussac,10,11 Serena Di Cosimo,12 José Baselga,13 Nadia Harbeck,14 Aleix Prat,corresponding author1,8,15,16 and Javier Cortés2,17,18
Manuscrito
NPJ BC
2021
NeoERIBULIN
